Understanding Gliomas

GBM brain tumors can be IDH wildtype or IDH mutated

Not all astrocytoma's with an IDH mutation are classified as grade 4 brain cancers

Most Astrocytoma brain tumors are either IDH1 or IDH2

Additional Facts About Gliomas

GLIOMAS: Gliomas present in a varying degree of aggressiveness, reflected in their grade, i.e. grade l – lV per and via clinical data established by the World Health Organization (WHO)

LOW-GRADE GLIOMAS (LGG): Slower growing glioma brain tumors that will reoccur (recurrent disease) that will progress and likely become more aggressive and more cancerous over time such as astrocytomas, oligodendrogliomas, ependymomas, etc.

HIGH-GRADE GLIOMAS (HGG): Rapidly growing/progressing brain tumors such as Glioblastoma/GBM’s.

11,000 low-grade gliomas are diagnosed in the U.S. annually.

IMPORTANT: 80% have an IDH mutation. IDH1/IDH2 mutations predict longer survival and response to the chemo Temodar/Temozolomide in LGG’s.

Gliomas with mutated IDH1/IDH2 have improved prognoses compared to gliomas with wild-type IDH (absence of IDH mutation). Gliomas classified as wild-type subgroups have a poor prognosis.

These mutations are isocitrate dehydrogenase (IDH) 1 and 2, originally discovered in 2009, occur in the vast majority of LGG’s and these mutations also drive increased methylation in gliomas.

IMPORTANT: Mutated IDH can now be detected by immunohistochemistry and magnetic resonance spectroscopy. Simply put, there are tests now that can determine if one’s LGG brain tumor tissue has an IDH1/IDH2 mutant.

IMPORTANT: IDH mutation testing is a valuable diagnostic, prognostic, and predictive biomarker for the management of patients with glioma brain tumors. Therefore, when tests are run to further classify your LGG, be sure these tests will indicate if your tumor tissue has an IDH1/IDH2 mutant so that targeted therapies can be used to treat your LGG brain cancer.

IMPORTANT: Patients seeking advanced treatments/clinical trials may consider Advocating and seeking out treatments and clinical trials that target the IDH1/IDH2 mutant instead of the traditional “wait & see” approach often used when treating LGG’s.

Supporting Articles & Videos

Download our App!

App Store

The apps you love. From a place you can trust. For over a decade, the App Store has proved to be a safe and trusted place to discover and download apps.

GET

Google Play

Enjoy millions of the latest Android apps, games, music, movies, TV, books, magazines & more. Anytime, anywhere, across your devices.

GET

CLINICAL TRIALS
We need a sentence or two summarizing what someone can find when searching this topic on the app.
PATIENT RESOURCES
We need a sentence or two summarizing what someone can find when searching this topic on the app.
RESEARCH
We need a sentence or two summarizing what someone can find when searching this topic on the app.
IMPORTANT ARTICLES
We need a sentence or two summarizing what someone can find when searching this topic on the app.
MEETINGS & EVENTS
We need a sentence or two summarizing what someone can find when searching this topic on the app.
CALLS TO ACTION
We need a sentence or two summarizing what someone can find when searching this topic on the app.
DONATE OR SUPPORT
We need a sentence or two summarizing what someone can find when searching this topic on the app.
BOOKSHOP
We need a sentence or two summarizing what someone can find when searching this topic on the app.
LOW GRADE GLIOMA
We need a sentence or two summarizing what someone can find when searching this topic on the app.

ENDBRAINCANCER INITIATIVE | CHRIS ELLIOTT FUND

Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614

DONATE

Our Case For Change

EBCI In The News

Patient Support Services

Patient Resource Center

VOLUNTEER WITH EBCI

GET IN TOUCH

corporate partners

upcoming events

resources

About us